{
    "relation": [
        [
            "",
            "Acyclovir 400mg Tablet Twice Daily",
            "Placebo Tablet Twice Daily"
        ],
        [
            "Description",
            "No text entered.",
            "No text entered."
        ]
    ],
    "pageTitle": "Acyclovir to Treat Patients Co-infected With HIV and Herpes Viruses in Uganda - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00405821?sect=X01256&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042992201.62/warc/CC-MAIN-20150728002312-00019-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 857796266,
    "recordOffset": 857780640,
    "tableOrientation": "VERTICAL",
    "textBeforeTable": "Reporting Groups All subjects were randomized to study arm, and initiated study treatment at the time of enrollment. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details 440 HIV+ subjects recruited in rural Rakai, Uganda within the Rakai Health Sciences Program mobile medical clinic during May 2007 thru November 2008 Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Drug: Acyclovir Drug: Placebo Interventions: HIV Infections Herpes Genitalis Conditions: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Double\u00a0Blind\u00a0(Subject,\u00a0Caregiver,\u00a0Investigator,\u00a0Outcomes\u00a0Assessor); \u00a0 Primary\u00a0Purpose:\u00a0Treatment Study Design: Interventional",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Acyclovir 400mg Tablet Twice Daily \u00a0 \u00a0 Placebo Tablet Twice Daily \u00a0 STARTED \u00a0 \u00a0 220 \u00a0 \u00a0 220 \u00a0 COMPLETED \u00a0 \u00a0 198 \u00a0 \u00a0 198 \u00a0 NOT COMPLETED \u00a0 \u00a0 22 \u00a0 \u00a0 22 \u00a0 Death \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 5 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 Lost to Follow-up \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 7 \u00a0 Protocol Violation \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 1 \u00a0",
    "hasKeyColumn": true,
    "keyColumnIndex": 0,
    "headerRowIndex": 0
}